Comparison of Steady‐State Blood Levels of Two Carbamazepine Formulations
- 1 February 1989
- Vol. 30 (1) , 67-70
- https://doi.org/10.1111/j.1528-1157.1989.tb05283.x
Abstract
The steady-state plasma level produced by brand-name carbamazepine (CBZ) (Tegretol, Ciba-Geigy) was compared with a generic formulation (Parke-Davis) in 10 subjects with partial epilepsy in a randomized, double-blind, cross-over clinical trial. In addition, seizure frequency and clinical and laboratory signs of toxicity were evaluated. Our results failed to show any difference in CBZ blood levels, seizure frequency, or clinical or laboratory signs of toxicity in patients receiving either the brand-name or generic formulation.Keywords
This publication has 6 references indexed in Scilit:
- Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic productNeurology, 1987
- Increased seizure frequency with generic primidonePublished by American Medical Association (AMA) ,1987
- Generic Drug Substitution RevisitedNew England Journal of Medicine, 1987
- Untoward Effects of Generic Carbamazepine TherapyArchives of Neurology, 1987
- Comparison of Alternative Outcome Measures for Antiepileptic Drug TrialsArchives of Neurology, 1986
- Bioavailability of Four Different Pharmaceutical Preparations of CarbamazepineActa Pharmacologica et Toxicologica, 1978